November 6, 2018 |
Filing
133
AMENDED OPINION AND ORDER re: 112 MOTION for Reconsideration: For the reasons set forth above, Impax's motion is GRANTED in part and DENIED in part. (Signed by Judge Edgardo Ramos on 11/6/2018) (jwh)
|
August 21, 2018 |
Filing
124
OPINION AND ORDER re: 118 LETTER MOTION for Oral Argument addressed to Judge Edgardo Ramos from Daniel H. Weiner dated Oct. 27, 2017 filed by Turing Pharmaceuticals AG, 111 LETTER MOTION for Oral Argument regarding Motio n for Clarification and/or Reconsideration addressed to Judge Edgardo Ramos from James E. Brandt dated October 13, 2017 filed by Impax Laboratories, Inc., 112 MOTION for Reconsideration re; 110 Memorandum & Opinion -- Moti on for Clarification and/or Reconsideration of the Court's September 29, 2017 Opinion and Order filed by Impax Laboratories, Inc. For the reasons set forth above, Impax's motion is GRANTED in part and DENIED in part. The parties a re directed to appear for a status conference September 12, 2018 at 11:00 a.m. at the United States Courthouse, 40 Foley Square, Courtroom 619, New York, NY 10007. The Clerk of the Court is respectfully directed to terminate the motions, Docs. 111, 112, and 118. It is SO ORDERED. (Status Conference set for 9/12/2018 at 11:00 AM in Courtroom 619, 40 Centre Street, New York, NY 10007 before Judge Edgardo Ramos.) (Signed by Judge Edgardo Ramos on 8/21/2018) (anc)
|
September 29, 2017 |
Filing
110
MEMORANDUM AND OPINION re: 92 MOTION for Partial Summary Judgment, 78 MOTION for Summary Judgment: Impax Laboratories, Inc. ("Impax") brought this action for declaratory judgment, breach of contract, and unjust enrichment aga inst Turing Pharmaceuticals AG ("Turing") on May 2, 2016, seeking to recover millions of dollars of rebate liability related to sales of the drug Daraprim. Turing counterclaimed, asserting breach of the same contract and breach of the duty of good faith and fair dealing. Pending before the Court are (1) Impax's motion for summary judgment on one of its breach of contract claims against Turing (Count 3) and Turing's counterclaims, Doc. 78, and (2) Turing's cross-motion fo r summary judgment on Impax's claim for declaratory judgment, Impax's breach of contract claims, and Turing's breach of contract counterclaim against Impax, Doc. 92. For the reasons set forth above, Impax's motion is GRANTED in pa rt and DENIED in part, and Turing's motion is GRANTED in part and DENIED in part. The parties are directed to appear for a status conference on October 18, 2017 at 2:30pm at the United States Courthouse, 40 Foley Square, Courtroom 619, New York, NY 10007. The Clerk of the Court is respectfully directed to terminate the motions, Docs. 78, 82, 92, and 96. (Signed by Judge Edgardo Ramos on 9/28/2017) (jwh)
|
November 16, 2016 |
Filing
99
OPINION AND ORDER. For the foregoing reasons, Defendant's motion to dismiss with prejudice Plaintiff's unjust enrichment claim (Count V of the Amended Complaint) is GRANTED. Plaintiff's motion for oral argument is DENIED as moot. The C lerk of the Court is respectfully directed to terminate the motions, Doc. 60 & 65. It is SO ORDERED. re: 60 MOTION to Dismiss Plaintiff's Unjust Enrichment Claim. filed by Turing Pharmaceuticals AG, 65 LETTER MOTION for Oral Argument addressed to Judge Edgardo Ramos from Daniel Adams dated August 18, 2016. Document filed by Impax Laboratories, Inc. (Signed by Judge Edgardo Ramos on 11/16/2017) (rjm)
|